Obesity: Legros JJ

Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC, Anonymous00084, Anonymous00085, Anonymous00086, Anonymous00087, Anonymous00088. · Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, and Los Angeles BioMedical Research Institute, Torrance, CA 90509, USA. · J Androl. · Pubmed #18772485 No free full text.

This publication has no abstract.

Legros JJ, Geenen V, Delmotte P. · Service Universitaire d'Endocrinologie, Unité de Psychoneuroendocrinologie, CHU et CHR Citadelle. · Rev Med Liege. · Pubmed #11256132 No free full text.

Abstract: During normal aging, there is a +/- 60% decrease of the endogenous GH secretion ("somatopause"). However it is safe to prescribe GH therapy only to those people who show a clear cut decrease of GH release as evidenced by low integrated 24 hr secretion and/or low plasma IGF-1. In our view, a complete clinical check up must also show, on the one hand, an abnormal decrease of the optimal quality of life and, on the other hand a willing to maintain a reasonable intellectual and physical activity in the absence of major clinical and biological abnormalities. The benefits are likely to be an increase of muscular strength and of exercise tolerance, a decrease of trabecular osteopenia, a decrease of abdominal obesity, an increase of immunocompetence and a general improvement of the "quality of life". A "pharmacological" prescription is contra-indicated whereas very low dose regimen could induce, through feed back mechanism, a putative decrease of endogenous GH-RH (and GHRPs?) function whose deleterious psychoneuroendocrine effects remain to be demonstrated.

Geenen V, Warzee E, Moutschen M, Legros JJ. · L'Université de Liège. · Rev Med Liege. · Pubmed #11294052 No free full text.

Abstract: The continuum of clinical phenotype between different autoimmune thyroid diseases and mainly the common pathophysiological mechanisms have lead to a novel classification of these disorders into three types: (1) Type 1 autoimmune thyroiditis (euthyroidism associated with the presence of anti-thyroglobulin and anti-thyroperoxydase autoantibodies); (2) Type 2 autoimmune thyroiditis or Hashimoto's disease (hypothyroidism with anti-thyroglobulin and anti-thyroperoxydase autoantibodies). Postpartum thyroiditis falls into this category and is characterized by transient hyperthyroidism followed by hypothyroidism; and (3) Type 3 autoimmune thyroiditis or Graves-Basedow's disease (hyperthyroidism with anti-TSH receptor "stimulating" auto-antibodies, often associated with anti-thyroglobulin and anti-thyroperoxydase autoantibodies). Thyroid orbitopathy often complicates Type 3 autoimmune thyroiditis and is thought to result from an autoimmune response against an autoantigen common to thyroid and orbital fibroblasts/adipose cells. We present the actualized knowledge about the immunological parameters that can be detected and quantified in autoimmune thyroid diseases, about the pathophysiological mechanisms involved in these disorders, and about the options of their treatment that are currently offered to the medical community.

Legros JJ. · Service Universitaire d'Endocrinologie, CHU, Sart Tilman. · Rev Med Liege. · Pubmed #10941312 No free full text.

Abstract: "Andropause" or "male climateric" refer to the term "menopause" in the women. The parallelism between both entities is however only partial since the decrease of gonadal function in the male is very different from one individual to the other. Some men present a gonadal deficiency together with an increase gonadotropin function as early as in the 40s while others show normal testicular function at 80 or later! It appears that besides genetic factors many life events (stress, obesity, sedentarity...) can "precipitate" testicular failure. Besides the major symptoms of sexual impotency and loss of libido, testosterone deficiency also induces reversible modification in lipid profile, muscle strength, bone density ... and on some cognitive and psychological parameters. It is therefore reasonable to treat androgen deficiency in early or late aging provided a cautious urological check-up has been realized before treatment. The mode of administration (i.m., p.o., or transdermal) will depend on the principal goal of the treatment and on the wish of the patient! An annual clinical and biological urological assessment is mandatory.